Clopidogrel linking evaluation of platelet response variability to mechanism of action

UMMS Affiliation

Department of Pediatrics



Document Type


Medical Subject Headings

Blood Platelets; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; *Platelet Function Tests; Ticlopidine; Time Factors; Treatment Outcome


Hematology | Oncology | Pediatrics


The antiplatelet agent clopidogrel, given alone or in addition to aspirin, is effective in reducing the composite end point of death from cardiovascular causes, nonfatal myocardial infarction, or stroke in patients with acute coronary syndromes. However, many patients receiving clopidogrel still sustain these poor outcomes. Furthermore, laboratory assays of platelet response(s) to clopidogrel show wide interindividual variability, with some patients being classified as “nonresponders” or “resistant” to clopidogrel. Understanding why these assays give such different results is essential to their possible future utility as guides to therapeutic decision-making and new drug development.

Rights and Permissions

Citation: J Am Coll Cardiol. 2005 Aug 16;46(4):646-7. doi 10.1016/j.jacc.2005.05.039

Related Resources

Link to article in PubMed

PubMed ID